CoChat

Angiotensin receptor blocker use and gastro‐oesophageal cancer survival: a population‐based cohort study

Open access
Busby, J., McMenamin, Ú., Spence, A., Johnston, B. T., Hughes, C., Cardwell, C. R. · 2018 · Alimentary Pharmacology & Therapeutics
Cited by 40

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Summary: Background: Angiotensin receptor blockers (ARB s; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy. There is considerable pre‐clinical evidence that ARB s can reduce cancer progression, particularly for gastric cancer. Despite this, epidemiological studies have yet to assess the impact of ARB use on gastro‐oesophageal cancer survival. Aim: To investigate the association between post‐diagnosis ARB use and gastro‐oesophageal cancer survival. Methods: We selected a cohort of patients with newly‐diagnosed gastro‐oesophageal cancer between 1998 and 2012 from English cancer registries. We linked to prescription and clinical records from the Clinical Practice Research Datalink, and to death records from the Office for National Statistics. We used time‐dependant Cox‐regression models to calculate hazard ratios (HR s) comparing gastro‐oesophageal cancer‐specific mortality between post‐diagnosis ARB users and non‐users, after adjusting for demographics, comorbidities and post‐diagnosis aspirin or statin use. Results: Our cohort included 5124 gastro‐oesophageal cancer patients, of which 360 used ARB s, and 3345 died due to their gastro‐oesophageal cancer during follow‐up. After adjustment, ARB users had moderately lower risk of gastro‐oesophageal cancer mortality than the non‐users (HR = 0.83, 95% CI 0.71‐0.98). There was evidence of a dose–response relationship with the lowest HR s observed among patients receiving at least 2 years of prescriptions (HR = 0.42, 95% CI 0.25‐0.72). Conclusions: In this large population‐based gastro‐oesophageal cancer cohort, we found moderately reduced cancer‐specific mortality among ARB users. However, confirmation in further independent epidemiological studies with sufficient staging information is required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.14388

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 40

Metadata

Authors
Busby, J., McMenamin, Ú., Spence, A., Johnston, B. T., Hughes, C., & Cardwell, C. R.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2017-11-03
Volume
47
Issue
2
Pages
279-288
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2761669428
Cited by
40
References
6
FWCI
3.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.